NextGen Precision Health & Ellis Fischel Cancer Center Science Seminar – June 15, 2023
The goal of the NextGen Precision Health & Ellis Fischel Cancer Center Science Seminar is to highlight transdisciplinary precision research taking place in the cancer field, provide opportunities for collaboration among researchers to build their own research efforts and promote clinical/researcher activity across the University of Missouri System and our partners.
For questions about this event, please reach out to Veronica Lemme.
Altering the Sarcoma Microenvironment
Speaker: Seth Michaels Pollack, MD, Associate Professor, Medicine, Hematology Oncology Division, and Steven T. Rosen, MD, Professor in Cancer Biology, Northwestern University
Date: June 15, 2023, 4:30-5:30 p.m.
Location: Roy Blunt NextGen Precision Health Building, Atkins Family Seminar Room
Dr. Seth Michaels Pollack is a medical oncologist who specializes in treating adult patients with sarcoma. His research is focused on the development of novel immunotherapies for patients with advanced sarcoma, particularly Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL). Dr. Pollack’s patient care philosophy is to provide care centered on his patient’s goals and desires and to fight as hard as he can to help cure patients.
About the Speaker
Dr. Seth Pollack, MD, is a medical oncologist and the director of the Sarcoma Program at the Lurie Cancer Center and the Steven T. Rosen, MD, Professor in Cancer Biology at the Feinberg School of Medicine at Northwestern University. Dr. Pollack worked previously at the University of Washington and Fred Hutchinson Cancer Research Center, which also is where he did his medical oncology fellowship. Dr. Pollack has expertise in both sarcoma treatment and cancer immunotherapy. As a physician-scientist, he runs a translational research lab, developing new immunotherapies designed for patients with advanced sarcoma. He has developed and led multiple experimental immunotherapy trials for sarcoma patients. His active collaboration with Dr. Jeff Bryan is shedding light on how IL-12-producing agents might be used to treat cancer in both dogs and humans.